Oncolytics Biotech Inc.
ONCYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. Valued at $102.5M, ONCY is a micro-cap name in its sector. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Market Cap
$102.5M
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
-3.58
EPS (TTM)
$-0.33
EPS (Fwd)
$-0.24
ROE
—
ROA
-188.5%
Cash
$5.5M
Total Debt
$508,000
Free CF
-$10.1M
52W Change
-30.6%
Annual Financials
Cash vs Debt
Where ONCY stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, ONCY finished 17.71% below its 150-day moving average ($0.96) and 21.78% below its 200-day moving average ($1.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONCY overbought or oversold?
At the July 9, 2026 close, ONCY's RSI(14) was 26.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oncolytics Biotech Inc. holds $5.5M in cash against $508K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$10.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oncolytics Biotech Inc.'s trajectory.